Literature DB >> 22722773

Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats.

Ilhan Gecit1, Servet Kavak, Mehmet Bilgehan Yüksel, Halil Basel, Hava Bektas, Hasan Ali Gümrükçüoglu, Ismail Meral, Halit Demir.   

Abstract

The aim of this study is to evaluate the influences of short-term treatment with levosimendan (chemical formula: C14H12N6O) on oxidative stress and some trace element levels in renal tissues of healthy rats. A total of 20 male Wistar-albino rats were randomly divided into two groups, each consisting of 10 rats. Animals in the first group were not treated with levosimendan and served as control. Animals in the second group were injected intraperitoneally with 12 µg/kg levosimendan and served as levosimendan group. Animals in both the groups were killed 3 days after the treatment, and their kidneys were harvested for the determination of tissue oxidant/antioxidant statues and trace element levels in renal tissues. The tissue malondialdehyde level was significantly (p < 0.001) lower in levosimendan group than in controls. The protective enzyme activities such as superoxide dismutase, catalase, and glutathione peroxidase and antioxidant glutathione level were significantly (p < 0.001) higher in levosimendan group than in controls. It was concluded that levosimendan reduced oxidative stress by avoiding lipid peroxidation and production of reactive oxygen species, and overactivating and/or increasing the protective antioxidant enzyme levels in renal tissues of rats. It is supposed that this experimental study provides beneficial data for clinicians in the management of renal tissue damage related to obstruction and/or ischemia.

Entities:  

Keywords:  Levosimendan; oxidant–antioxidant level; oxidative stress; rat kidney; trace element level

Mesh:

Substances:

Year:  2012        PMID: 22722773     DOI: 10.1177/0748233712451773

Source DB:  PubMed          Journal:  Toxicol Ind Health        ISSN: 0748-2337            Impact factor:   2.273


  7 in total

1.  Levosimendan affects oxidative and inflammatory pathways in the diaphragm of ventilated endotoxemic mice.

Authors:  Willem-Jan M Schellekens; Hieronymus W H van Hees; Marianne Linkels; P N Richard Dekhuijzen; Gert Jan Scheffer; Johannes G van der Hoeven; Leo M A Heunks
Journal:  Crit Care       Date:  2015-03-02       Impact factor: 9.097

2.  Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

Authors:  Elena Grossini; Kevin Bellofatto; Serena Farruggio; Lorenzo Sigaudo; Patrizia Marotta; Giulia Raina; Veronica De Giuli; David Mary; Piero Pollesello; Rosalba Minisini; Mario Pirisi; Giovanni Vacca
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

3.  Levosimendan Reduces Lung Injury in a Canine Model of Cardiopulmonary Bypass.

Authors:  Junbo Feng; Haiyuan Liu; Jiayi Chen; Jiyuan Wang; Zhuang Liu; Shenglin Ge
Journal:  Korean Circ J       Date:  2016-05-02       Impact factor: 3.243

4.  Differential effects of inotropes and inodilators on renal function in acute cardiac care.

Authors:  Endre Zima; Dimitrios Farmakis; Piero Pollesello; John T Parissis
Journal:  Eur Heart J Suppl       Date:  2020-05-15       Impact factor: 1.803

5.  Upregulation of antioxidant nuclear factor erythroid 2-related factor 2 and its dependent genes associated with enhancing renal ischemic preconditioning renoprotection using levosimendan and cilostazol in an ischemia/reperfusion rat model.

Authors:  Mona K Tawfik; Samy Makary; Mohammed M Keshawy
Journal:  Arch Med Sci       Date:  2021-01-28       Impact factor: 3.318

6.  Exercise Capacity Is Improved by Levosimendan in Heart Failure and Sarcopenia via Alleviation of Apoptosis of Skeletal Muscle.

Authors:  Di Wang; Ming Song; Long-Fei Shen; Lu Han; Ping Zhu; Xu Jia; Guo-Kai Shang; Yuan Cao; Wei Zhang; Ming Zhong; Zhi-Hao Wang
Journal:  Front Physiol       Date:  2022-01-20       Impact factor: 4.566

Review 7.  Renal effects of levosimendan: a consensus report.

Authors:  Mehmet B Yilmaz; Elena Grossini; José C Silva Cardoso; István Édes; Francesco Fedele; Piero Pollesello; Matti Kivikko; Veli-Pekka Harjola; Julia Hasslacher; Alexandre Mebazaa; Andrea Morelli; Jos le Noble; Anders Oldner; Ignacio Oulego Erroz; John T Parissis; Alexander Parkhomenko; Gerhard Poelzl; Sebastian Rehberg; Sven-Erik Ricksten; Luís M Rodríguez Fernández; Markku Salmenperä; Mervyn Singer; Sascha Treskatsch; Bojan Vrtovec; Gerhard Wikström
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.